KWESST Micro Systems 株価情報 (NASDAQ: KWE)

最新ニュース KWESST Micro Systems (NASDAQ:KWE) 株価情報

KWESST Micro Systems

KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.

News

Pre-Market Outlook

Markets

Movers

AYRO

CLDI

CLNN

GDHG

GOOGL

MREO

OBLG

ORCL

PETS

PIXY

SRFM

THMO

TNXP

WLGS

オラクル・コーポレーション (NYSE:ORCL) の株価は、同社が第4四半期決算を発表した後、本日のプレマーケット取引で急騰しました。オラクルは自社の2021年4月～6月期決算において、予想を下回る決算を発表しました。同社は、アルファベット（Alphabet Inc）（NASDAQ:GOOGL）（NASDAQ:GOOG）のGoogle Cloudと提携することも発表しました。

オラクルの株価9%上昇の理由

KWESST Micro Systems Inc. - common stock, no R/S concurrent with offering

KWESST Micro Systems Inc

KraneShares Trust KraneShares CSI China Internet ETF

NBT Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTB#NASDAQ">NBTB</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.74 by 8.11 percent. This is a 17.65 percent increase over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $154.68 million which beat the analyst consensus estimate of $151.05 million by 2.40 percent. This is a 10.04 percent increase over sales of $140.57 million the same period last year.

Earnings

Earnings Beats

NBTB

NBT Bancorp Q1 Adj. EPS $0.80 Beats $0.74 Estimate, Sales $154.68M Beat $151.05M Estimate

Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $0.92 by 19.57 percent. This is a 23.6 percent increase over earnings of $0.89 per share from the same period last year. The company reported quarterly sales of $423.54 million which beat the analyst consensus estimate of $422.05 million by 0.35 percent. This is a 6.85 percent increase over sales of $396.37 million the same period last year.

Federated Hermes Q1 Adj. EPS $1.10 Beats $0.92 Estimate, Sales $423.54M Beat $422.05M Estimate

General

SES AI Authorizes Repurchase Up To $30M Of Its Class A Common Stock

First Western Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYFW#NASDAQ">MYFW</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.23 by 86.96 percent. This is a 65.38 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $24.80 million which beat the analyst consensus estimate of $24.10 million by 2.88 percent. This is a 6.21 percent increase over sales of $23.35 million the same period last year.

MYFW

First Western Financial Q1 EPS $0.43 Beats $0.23 Estimate, Sales $24.80M Beat $24.10M Estimate

Universal Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) reported quarterly earnings of $0.23 per share which missed the analyst consensus estimate of $0.48 by 52.08 percent. This is a 88.44 percent decrease over earnings of $1.99 per share from the same period last year. The company reported quarterly sales of $382.39 million which missed the analyst consensus estimate of $400.60 million by 4.55 percent. This is a 22.26 percent decrease over sales of $491.91 million the same period last year.

Earnings Misses

Universal Logistics Hldgs Q1 EPS $0.23 Misses $0.48 Estimate, Sales $382.39M Miss $400.60M Estimate

Middlefield Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBCN#NASDAQ">MBCN</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.46 by 30.43 percent. This is a 17.65 percent increase over earnings of $0.51 per share from the same period last year.

MBCN

Middlefield Banc Q1 EPS $0.60 Beats $0.46 Estimate

World Kinect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WKC#NYSE">WKC</a>) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.45 by 6.67 percent. This is a 2.13 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $9.45 billion which missed the analyst consensus estimate of $10.47 billion by 9.73 percent. This is a 13.68 percent decrease over sales of $10.95 billion the same period last year.

World Kinect Q1 Adj. EPS $0.48 Beats $0.45 Estimate, Sales $9.45B Miss $10.47B Estimate

Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) narrows FY2025 FFO guidance from $3.83-$3.88 to $3.84-$3.87 vs $3.89 analyst estimate..

Guidance

GLPI

Gaming and Leisure Props Narrows FY2025 FFO Guidance from $3.83-$3.88 to $3.84-$3.87 vs $3.89 Est

Eastman Chemical Q1 Adj. EPS $1.91 Beats $1.89 Estimate, Sales $2.29B Miss $2.33B Estimate

Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced Thursday that it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">the next four years</a>.
As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44976531/thermo-fisher-scientific-invests-to-enhance-u-s-innovation-and-support-customers-manufacturing" rel="noreferrer noopener">medicines in America</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966205/analyst-sees-opportunity-in-danaher-stock-as-sentiment-improves" rel="noreferrer noopener">Analyst Sees Opportunity In Danaher Stock As Sentiment Improves</a>
These additional investments to the company&#8217;s American manufacturing capacity support a resilient U.S. healthcare supply chain and will have a strong multiplier effect across the American economy.
The $2 billion investment over the next four years includes:
<ul>
<li>$1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations</li>
<li>Complemented by $500 million in R&amp;D focused on high-impact innovation</li>
</ul>
Thermo Fisher CEO Marc N. Casper explained that by expanding in the U.S., the company ensures that &#8220;life-saving medicines and therapies will continue to be developed and produced in America for decades to come.&#8221;
This investment builds on Thermo Fisher&#8217;s 64 U.S. manufacturing operations in 37 states.
The company also invests $1 billion annually in R&amp;D in the U.S.
Over the next four years, the company will continue to expand its impact in the U.S. by creating high-paying jobs, adding manufacturing and lab services capacity, and investing in research and development.
On Wednesday, Thermo Fisher said that it expects U.S.-China tariffs to hurt sales in China for products made in the U.S. The company estimates this will reduce revenue by $400 million in 2025. These tariffs will also raise the cost of parts and subassemblies <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966173/thermo-fisher-beats-q1-estimates-lowers-full-year-forecast-as-tariffs-and-costs-take-a-toll" rel="noreferrer noopener">sourced from China</a>.
After accounting for lower sales and higher costs—despite efforts to reduce the impact—the company expects adjusted operating income to take a $375 million hit compared to previous guidance.
Analyst Reactions on Thursday:
<ul>
<li>Baird maintains Thermo Fisher Scientific with an Outperform, lowering the price target from $603 to $573.</li>
<li>Wells Fargo maintains Thermo Fisher with an Overweight rating and lowers the price target from $580 to $570.</li>
<li>Evercore ISI maintains Thermo Fisher with an Outperform, lowering the price target from $585 to $500.</li>
<li>Stifel reaffirms the Buy rating for Thermo Fisher, lowering the price target from $665 to $620.</li>
</ul>
Price Action: TMO stock is down 2.57% at $420.55 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44981281/french-drugmaker-sanofi-clocks-20-q1-profit-growth-forecasts-strong-rebound-in-annual-profit" target="_blank" rel="noreferrer noopener">French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Price Target

Analyst Ratings

Trading Ideas

Thermo Fisher Doubles Down On US Manufacturing In $2B Expansion Plan

Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) reported quarterly earnings of $0.96 per share which met the analyst consensus estimate. This is a 4.35 percent increase over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $395.24 million which missed the analyst consensus estimate of $396.52 million by 0.32 percent. This is a 5.13 percent increase over sales of $375.96 million the same period last year.

Gaming and Leisure Props Q1 FFO $0.96, Inline, Sales $395.24M Miss $396.52M Estimate

Dividends

GOOG

Alphabet Raises Quarterly Dividend From $0.20 To $0.21 Per Share

WIIM

Alphabet shares are trading higher following better-than-expected Q1 financial results.

Rosenblatt analyst Catharine Trebnick maintained a Buy rating on Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) on Thursday,<a href="https://www.benzinga.com/quote/ZM/analyst-ratings" target="_blank" rel="noreferrer noopener"> lowering the price forecast from $95 to $90.</a>
Trebnick cautioned about growing macroeconomic uncertainty and potential tariff-related challenges that may hinder the company&#8217;s ability to expand revenue streams beyond the U.S. market.
The new forecast reflects a valuation of approximately 4.2 times the projected 2027 revenue, down from the previous multiple of 4.5 times.
While Zoom is trading at 3.0 times its enterprise value to estimated 2027 sales—a level consistent with the broader SaaS group average—it is growing revenue at 3% year over year, compared to the group&#8217;s 6%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44965915/northrop-grummans-strategic-edge-lies-in-classified-space-and-electronic-warfare-programs-but-market-focused-on-short-term-issues-analyst" rel="noreferrer noopener">Northrop Grumman&#8217;s Flight Path Recalculated: Analyst Trims Forecast, Reiterates Buy</a>
However, the analyst notes that this valuation is still reasonable given Zoom&#8217;s strong financial footing, including a substantial $7.8 billion cash reserve and a free cash flow margin of 37%, which significantly exceeds the industry average of 26%.
Trebnick trimmed the revenue growth expectations for Zoom, now forecasting a 2.2% increase for FY26—below the company&#8217;s FY25 guidance of 2.7% at the midpoint.
For FY25, the analyst estimates revenue at $4.768 billion, reflecting 2.6% growth and slightly below both their previous estimate and the Street consensus of $4.788 billion.
FY27 revenue is also adjusted downward to $4.935 billion, implying 3.5% growth and again falling short of the consensus estimate of $4.949 billion.
As a result of these lower projections, adjusted operating income for FY25 is revised to $1.854 billion with a margin of 38.9%, just under the Street&#8217;s forecast, Trebnick writes.
Due to reduced sales volume expectations, the analyst now projects FY26 pro forma EPS at $5.34, unchanged from their previous estimate.
Looking further ahead, with anticipated revenue growth of just 3.5% in FY27, the EPS forecast has been modestly lowered to $5.48 from $5.50, the analyst writes.
Price Action: ZM shares are trading higher by 3.16% to $75.28 at last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44962890/3-key-signals-say-its-time-to-invest-in-this-forgotten-market-heres-how" target="_blank" rel="noreferrer noopener">3 Key Signals Say It&#8217;s Time To Invest In This &#8216;Forgotten&#8217; Market, Here&#8217;s How</a></li>
</ul>
Photo: Shutterstock

Equities

Zoom Faces International Growth Risks Amid Macroeconomic And Tariff Headwinds: Analyst

Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) has outperformed the market over the past 15 years by 2.78% on an annualized basis producing an average annual return of 13.49%. Currently, Accenture has a market capitalization of $182.56 billion. 
Buying $100 In ACN: If an investor had bought $100 of ACN stock 15 years ago, it would be worth $659.45 today based on a price of $291.41 for ACN at the time of writing.
<h3>Accenture's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745525714_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

First Business Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.27 by 3.94 percent. This is a 26.92 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $33.30 million which missed the analyst consensus estimate of $40.13 million by 17.01 percent. This is a 8.20 percent decrease over sales of $36.28 million the same period last year.

FBIZ

First Business Finl Servs Q1 EPS $1.32 Beats $1.27 Estimate, Sales $33.30M Miss $40.13M Estimate

Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) reported quarterly losses of $(0.06) per share. This is a 90 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $40.74 million which beat the analyst consensus estimate of $16.30 million by 149.97 percent. This is a 0.84 percent decrease over sales of $41.09 million the same period last year.

GNFT

Genfit FY EPS $(0.06) Up From $(0.62) YoY, Sales $40.74M Beat $16.30M Estimate

Universal Insurance Hldgs Q1 Adj. EPS $1.44 Beats $1.26 Estimate, Sales $394.87M Beat $354.97M Estimate

Rocket Lab USA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) has been tapped by defense contractor Kratos Defense &amp; Security Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) to carry out a <a href="https://www.benzinga.com/pressreleases/25/04/b44965385/rocket-lab-awarded-new-haste-launch-contract-for-the-dod-by-kratos">hypersonic flight test </a>for the U.S. Department of Defense as part of the MACH-TB 2.0 program.
The mission, set to occur no sooner than early 2026, will lift off from Rocket Lab's Launch Complex 2 located on Wallops Island, Virginia. 
It represents the initial full-scale test flight granted by Kratos through the $1.45 billion MACH-TB 2.0 initiative, aimed at accelerating the development and evaluation of hypersonic technologies.
Also Read: <a href="https://www.benzinga.com//node/44629352">Rocket Lab Unveils Advanced Space-Grade Radios For Deep Space Missions</a>
Rocket Lab joined the MACH-TB 2.0 roster in January, following its successful support of multiple hypersonic tests under the original MACH-TB program in 2023. 
The company previously executed three missions for the Department of Defense, two of which launched just three weeks apart from the same Virginia site.
&#8220;In less than two years since its first launch, HASTE has quickly emerged as a leading commercial test platform of hypersonic systems. With our operational speed and cadence, and the ability to serve multiple mission profiles all in one platform, HASTE is helping to move the needle on hypersonic innovation,&#8221; said founder and CEO Sir Peter Beck.
For the upcoming test, Rocket Lab will deploy its HASTE launch vehicle, a suborbital adaptation of the company's Electron rocket. 
Designed for high-speed performance and flexible payload capacity, HASTE features lightweight carbon composite construction, additively manufactured engines, and a reconfigured Kick Stage tailored to support larger hypersonic experiment loads. 
The rocket can propel test systems at speeds exceeding 7.5 kilometers per second, allowing trials of air-breathing propulsion, glide bodies, and atmospheric reentry systems.
Beyond the MACH-TB program, HASTE has been added to several international defense frameworks. It is now listed under the <a href="https://www.benzinga.com/25/04/44814484/rocket-lab-stock-is-ripping-higher-tuesday-heres-why">U.S. Air Force's $46 billion Enterprise-Wide Agile Acquisition Contract</a> (EWAAC), granting Rocket Lab eligibility to compete for further defense-related launch services.
Price Action: RKLB shares traded higher by 8.21% at $21.96 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44990084/taiwan-semiconductor-to-begin-production-of-14-nm-chips-in-2028-enhancing-ai-and-smartphone-performance">Taiwan Semiconductor To Begin Production Of Advanced 1.4nm Chips In 2028</a></li>
</ul>

Tech

KTOS

RKLB

Why Is Rocket Lab Stock Trading Higher On Thursday?

On April&nbsp;22, 2025, The Boeing Company (the "Company") entered into a Membership Interest Purchase Agreement (the "Agreement") among the Company, JNPR Aero, LLC ("JNPR Aero") and Project Maroon, LLC ("Buyer" and, together with the Company and JNPR Aero, the "Parties"), whereby the Company agreed to sell all of its interests in JNPR Aero, together with all of its interests in certain of its affiliates that operate, or that, following the Pre-Closing Reorganization (as defined in the Agreement) will operate, certain global aviation data and software products, to Buyer for a purchase price of $10.55&nbsp;billion (subject to customary purchase price adjustments).
Under the Agreement, each of the Parties made customary representations, warranties and covenants, and following the Closing (as defined in the Agreement), Buyer and the Company have agreed to provide one another with customary indemnities with respect to certain assets and liabilities allocated between their respective post-transaction businesses pursuant to the Pre-Closing Reorganization and the consummation of the transactions contemplated by the Agreement.

Contracts

Asset Sales

Boeing To Sell JNPR Aero And Related Global Aviation Data And Software Assets To Project Maroon For $10.55B In Major Strategic Divestiture

Press Releases

KWESST Secures Contract Valued at up to $48M for Software Development Services with Thales Canada to Support Canadian Army Digital Modernization

Stocks to Watch Under $1: MSS, KWE, PRSO, PNPN.V, TNXP, KAVL for December 2024

"Breakthrough Stocks to Watch: WATT, STEM, PNPN.V, NXU, REKR Powering Santa Rally Momentum, more inside!"

INTZ

KAVL

KWESW

PNPNF

PRSO

REKR

STEM

TSX:KWE

TSXV:KWE

TSXV:PNPN

WATT

オラクル・コーポレーション (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) の株価は、同社が<a href="https://www.benzinga.com/news/earnings/24/06/39280057/oracle-misses-q4-earnings-stock-surges-on-booming-ai-demand-openai-contract-partnership-with-google">第4四半期決算を発表した後、本日のプレマーケット取引で急騰しました。</a>
オラクルは自社の2021年4月～6月期決算において、予想を下回る決算を発表しました。同社は、アルファベット（Alphabet Inc）（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>）（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>）のGoogle Cloudと提携することも発表しました。
プレマーケット取引でオラクルの株は前場で135.00ドルに急騰しました。
以下は、プレマーケット取引で動いている他の銘柄です。
<h3 class="wp-block-heading">株価最大上昇</h3>
<ul>
<li>本日のプレマーケット取引でGolden Heaven Group Holdings Ltd（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>）の株は0.3049ドル（70.3%高）に上昇しました。</li>
<li>本日のプレマーケット取引でWANG＆amp;LEE GROUP, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>）の株は0.8760ドル（43.1%高）に上昇し、火曜日には16%上昇していました。</li>
<li>本日のプレマーケット取引でSurf Air Mobility Inc.（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>）の株は0.3860ドル（38%高）となりました。 Surf Air MobilityはブラジルのCessna Caravanを運営するAsta社に電動パワートレインを供給する合意を締結しました。</li>
<li>本日のプレマーケット取引でBeamr Imaging Ltd.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMR#NASDAQ">BMR</a>）の株は5.64ドル（28.2%高）に上昇しました。 Beamrは、同社のクラウドソリューションが現在、Oracle Cloud Marketplaceで利用可能であると述べています。</li>
<li>本日のプレマーケット取引でCastellum, Inc.（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>）の株は0.2410ドル（24.9%高）に上昇しました。</li>
<li>火曜日にTrianが同社に出資しているとの報告に続き、本日のプレマーケット取引でRentokil Initial plc（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>）の株は30.01ドル（11.5%高）に上昇しています。</li>
<li>本日のプレマーケット取引でThe Aaron&#8217;s Company, Inc.（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAN#NYSE">AAN</a>）の株は8.88ドル（10.9%高）に上昇しました。</li>
<li>本日のプレマーケット取引でMereo BioPharma Group plc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>）の株は3.90ドル（10.8%高）に上昇しました。UltragenyxとMereoは、第2/3部分の第2相Orbit試験の14か月の結果を発表しました。</li>
<li>本日のプレマーケット取引でAyro, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>）の株は0.8991ドル（9.6%高）に上昇しました。</li>
</ul>
<h3 class="wp-block-heading">株価最大下落</h3>
<ul>
<li>ナスダックは、ThermoGenesis Holdings, Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>）の株がプレマーケット取引で49.8%下落し0.2691ドルに低下したことを受け、同社のリスティング維持要請を拒否しました。同社の株は2024年6月17日の取引開始時に取引が停止されます。</li>
<li>火曜日には4%下落していたことを受け、本日のプレマーケット取引でClene Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>）の株は0.31ドル（24.7%下落）に低下しました。</li>
<li>本日のプレマーケット取引でTonix Pharmaceuticals Holding Corp（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>）の株は1.61ドル（24.4%下落）に下落しました。同社は株式の公開募集を発表しました。</li>
<li>火曜日の取引で17%上昇した後、本日のプレマーケット取引でKWESST Micro Systems Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>）の株は0.7965ドル（21.9%下落）に下落しました。KWESST Micro Systemsは最近、ソフトウェア開発サービスに関するThales Canada社から最大4800万カナダドル相当のサブ契約を受けました。</li>
<li>火曜日には5%上昇していたことを受け、本日のプレマーケット取引でShiftPixy, Inc（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>）の株は1.32ドル（14.3%下落）に低下しました。</li>
<li>火曜日には5%下落していたことを受け、本日のプレマーケット取引でOblong, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>）の株は0.1723ドル（14.2%下落）に低下しました。Obglongは最近、Dwellwell Analyticsを取得するための拘束力のない意向書に署名しました。</li>
<li>火曜日には混合の四半期決算を発表し、本日のプレマーケット取引でPetMed Express, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>）の株は4.06ドル（13.8%下落）に低下しました。同社は、四半期決算において難しいマクロ環境と業界の動向が結果に悪影響を及ぼしたと述べています。</li>
<li>火曜日には13%上昇した後、本日のプレマーケット取引でmF International Limited（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>）の株は0.99ドル（13%下落）に低下しました。</li>
<li>火曜日には32%上昇した後、本日のプレマーケット取引でCalidi Biotherapeutics, Inc.（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NASDAQ">CLDI</a>）の株は0.2370ドル（12.2%下落）に低下しました。Calidi Biotherapeuticsは最近、肺がんおよび転移性固形腫瘍のためのCalidiのRTNovaウイロセラピーを進めるためにSIGA Technologies社と協力することを発表しました。</li>
<li>火曜日に23%下落した後、本日のプレマーケット取引でBig Tree Cloud Holdings Limited（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>）の株は2.45ドル（11.9%下落）に低下しました。Big Tree Cloudは最近、Plutonian Acquisition Corp とのビジネスコンビネーションを完了したことを発表しました。</li>
</ul>

Comments

KWESST Micro Systems

ニュース

最新ニュース KWESST Micro Systems (NASDAQ:KWE) 株価情報

水曜日, 6 12, 2024

ニュース

パートナーシップ

ベンジンガ・グローバル